U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.

To tackle this, Save the Children and GSK are offering a $100,000 innovation grant to support groundbreaking community ideas that demonstrate potential to increase immunisation coverage sustainably.

GSK wants to take full control of an over-the-counter joint venture with Novartis, and may sell its Horlicks business to fund the £9.2 billion acquisition.

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

In addition, GSK's decision to replace the brand-name inhaler with a higher-cost authorized generic had lowered access for low-income patients, Hassan said.

Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.